{"title":"在体外对美罗培南敏感的肠杆菌中检测碳青霉烯酶。","authors":"Luana Silva Dornelles, Mariana Preussler Mott, Gabriela da Silva Collar, Luciana Giordani, Rodrigo Minuto Paiva, Larissa Lutz","doi":"10.1016/j.eimce.2024.07.008","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Carbapenemase-producing Enterobacterales (CPE) is a global threat. We evaluate the prevalence of CPE among isolates categorized as meropenem-susceptible, but that meet the European Committee on Antimicrobial Susceptibility Testing (EUCAST) screening cut-off values for carbapenemase detection, and analyze the susceptibility of these isolates to new available drugs.</p><p><strong>Methods: </strong>We analyzed 257 isolates from patients hospitalized in a tertiary hospital in Brazil, from July 2022 to April 2023. Only isolates that met the screening cut-off values established by EUCAST for detection of carbapenemases were analyzed (i.e. meropenem inhibition zones of 25-27mm by disk diffusion). The detection of carbapenemases was performed by immnunochromatographic testing and confirmed by high-resolution melting-PCR (HRM-qPCR).</p><p><strong>Results: </strong>We identified 12 (4.7%) CPE including 7 KPC, 4 NDM, and 1 OXA-48-like. The isolates were susceptible to ceftazidime-avibactam (72.7%), meropenem-vaborbactam (100%), imipenem-relebactam (63.6%) and ceftolozane-tazobactam (36.4%).</p><p><strong>Conclusion: </strong>We highlight the importance of tracking carbapenemases for epidemiological control and therapeutic guidance.</p>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 1","pages":"32-35"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Detection of carbapenemases in Enterobacterales susceptible in vitro to meropenem.\",\"authors\":\"Luana Silva Dornelles, Mariana Preussler Mott, Gabriela da Silva Collar, Luciana Giordani, Rodrigo Minuto Paiva, Larissa Lutz\",\"doi\":\"10.1016/j.eimce.2024.07.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Carbapenemase-producing Enterobacterales (CPE) is a global threat. We evaluate the prevalence of CPE among isolates categorized as meropenem-susceptible, but that meet the European Committee on Antimicrobial Susceptibility Testing (EUCAST) screening cut-off values for carbapenemase detection, and analyze the susceptibility of these isolates to new available drugs.</p><p><strong>Methods: </strong>We analyzed 257 isolates from patients hospitalized in a tertiary hospital in Brazil, from July 2022 to April 2023. Only isolates that met the screening cut-off values established by EUCAST for detection of carbapenemases were analyzed (i.e. meropenem inhibition zones of 25-27mm by disk diffusion). The detection of carbapenemases was performed by immnunochromatographic testing and confirmed by high-resolution melting-PCR (HRM-qPCR).</p><p><strong>Results: </strong>We identified 12 (4.7%) CPE including 7 KPC, 4 NDM, and 1 OXA-48-like. The isolates were susceptible to ceftazidime-avibactam (72.7%), meropenem-vaborbactam (100%), imipenem-relebactam (63.6%) and ceftolozane-tazobactam (36.4%).</p><p><strong>Conclusion: </strong>We highlight the importance of tracking carbapenemases for epidemiological control and therapeutic guidance.</p>\",\"PeriodicalId\":72916,\"journal\":{\"name\":\"Enfermedades infecciosas y microbiologia clinica (English ed.)\",\"volume\":\"43 1\",\"pages\":\"32-35\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Enfermedades infecciosas y microbiologia clinica (English ed.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.eimce.2024.07.008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedades infecciosas y microbiologia clinica (English ed.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.eimce.2024.07.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Detection of carbapenemases in Enterobacterales susceptible in vitro to meropenem.
Introduction: Carbapenemase-producing Enterobacterales (CPE) is a global threat. We evaluate the prevalence of CPE among isolates categorized as meropenem-susceptible, but that meet the European Committee on Antimicrobial Susceptibility Testing (EUCAST) screening cut-off values for carbapenemase detection, and analyze the susceptibility of these isolates to new available drugs.
Methods: We analyzed 257 isolates from patients hospitalized in a tertiary hospital in Brazil, from July 2022 to April 2023. Only isolates that met the screening cut-off values established by EUCAST for detection of carbapenemases were analyzed (i.e. meropenem inhibition zones of 25-27mm by disk diffusion). The detection of carbapenemases was performed by immnunochromatographic testing and confirmed by high-resolution melting-PCR (HRM-qPCR).
Results: We identified 12 (4.7%) CPE including 7 KPC, 4 NDM, and 1 OXA-48-like. The isolates were susceptible to ceftazidime-avibactam (72.7%), meropenem-vaborbactam (100%), imipenem-relebactam (63.6%) and ceftolozane-tazobactam (36.4%).
Conclusion: We highlight the importance of tracking carbapenemases for epidemiological control and therapeutic guidance.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
